References
- 1. PERRIN P., CAILLARD S., JAVIER RM., et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. American Journal of Transplantation. 2013; 13(10): 2653-2663.
- 2. MAZZAFERRO S., PASQUALI M., TAGGI F., et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clinical Journal of the American Society of Nephrology. 2009; 4(3): 685-690.
- 3. GWINNER W., SUPPA S., MENGEL M., et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. American Journal of Transplantation. 2005; 5(8): 1934-1941.
- 4. Cohen JB., Gordon CE., Balk EM., Francis JM., et al. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: A systematic review and meta-analysis. Transplantation. 2012; 94(10): 1041-1048.
- 5. PASCHOALIN RP., TORREGROSA JV., SÁNCHEZ-ESCUREDO A., BARROS X., DURÁN CE., CAMPISTOL JM., et al Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up. Transplantation Proceedings. 2012; 44(9): 2588-2589.
- 6. LINDBERG J.S., CULLETON B., WONG G., et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Journal of the American Society of Nephrology. 2005; 16(3): 800-807.
- 7. PALMER S.C., NISTOR I., CRAIG J.C., et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Medicine. 2013; 10(4).
- 8. PASCHOALIN R.P., TORREGROSA J.V., BARROS X., DURAN C.E., CAMPISTOL J.M. et al. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal. Transplantation proceedings. 2012; 44(8): 2376-2378.
- 9. TORREGROSA J.V., MORALES E., DIAZ J.M., et al. Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study. Nephrology. 2014; 19(2): 84-93.
- 10. MESSA P., CAFFORIO C., ALFIERI C., et al. Clinical impact of hypercalcemia in kidney transplant. International Journal of Nephrology. 2011; 2011:9.
- 11. MUIRHEAD N., ZALTMAN J.S., GILL J.S., et al. Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice. Clinical Transplantation. 2014; 28(2): 161-165.
- 12. TORREGROSA J.V., BARROS X. Management of hypercalcemia after renal transplantation. Nefrologia. 2013; 33(6): 751-757.
- 13. EVENEPOEL P., CLAES K., KUYPERS D.R., DEBRUYNE F., VANRENTERGHEM Y., et al. Parathyroidectomy after successful kidney transplantation: a single center study. Nephrology Dialysis Transplantation. 2007; 22(6): 1730-1737.
- 14. ROJAS E., CARLINI R.G., CLESCA P., et al. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney International. 2003; 63(5): 1915-1923.
- 15. NAGANO N., NEMETH E.F. Functional proteins involved in regulation of intracellular Ca2+ for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetic. Journal of Pharmacological Sciences. 2005; 97(3): 355-360.
- 16. LINDBERG J.S., CULLETON B., WONG G., et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Journal of the American Society of Nephrology. 2005; 16(3): 800-807.
- 17. GUERRA R., SAAVEDRA I.A., FERNANDEZ E.J., et al. Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with Cinacalcet. Journal of Nephrology. 2011; 24(1): 78-82.